This site is intended for healthcare professionals
News

European Commission approves Sunosi to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy, Jazz Pharma

Read time: 1 mins
Published:21st Jan 2020
Jazz Pharmaceuticals plc announced that the European Commission approved Sunosi (solriamfetol) to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved to treat EDS in adults living with narcolepsy or OSA and the only licensed therapy in the European Union for the treatment of EDS in adults living with OSA.
Condition: Sleeping Disorders/Narcolepsy
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.